BHRT vs Synthetic HRT
BHRT uses hormones (estradiol, progesterone, testosterone) that are molecularly identical to those produced endogenously. Conventional synthetic HRT historically used conjugated equine estrogens and synthetic progestins (e.g., medroxyprogesterone). The molecular distinction matters for metabolism, receptor profile, and the evidence base on cardiovascular and breast outcomes.
BHRT is the provider-reviewed pathway when the goal is hormone replacement using molecules identical to endogenous production, with delivery (transdermal estradiol, micronized progesterone) matched to candidacy and the standardized panel.
Explore pathwayConventional synthetic HRT remains in use in specific clinical contexts but is not the modern default for most BHRT candidates.
Educational. Final pathway selection is provider-reviewed via synchronous video consultation against your biomarkers, history, and goals.
Frequently asked
Did the WHI study apply to BHRT?
The original WHI used conjugated equine estrogens plus medroxyprogesterone — not bioidentical estradiol and micronized progesterone. The risk profile of those specific molecules does not generalize cleanly to BHRT.
Is 'bioidentical' the same as 'compounded'?
No. Bioidentical refers to molecular structure. Compounded refers to pharmacy preparation. BHRT can use FDA-approved bioidentical products or compounded preparations — the distinction is reviewed in candidacy.
Take the optimization assessment.
The adaptive assessment maps your symptoms, history, and goals to candidate pathways — and routes you into provider review.
Begin assessment
